이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Seelos Therapeutics 관리

관리 기준 확인 3/4

Seelos Therapeutics' CEO는 Raj Mehra, Jan2019 에 임명되었습니다 의 임기는 5.42 년입니다. 총 연간 보상은 $ 1.73M, 34% 로 구성됩니다. 34% 급여 및 66% 보너스(회사 주식 및 옵션 포함). 는 $ 19.44K 가치에 해당하는 회사 주식의 0.89% 직접 소유합니다. 19.44K. 경영진과 이사회의 평균 재임 기간은 각각 4.1 년과 5.4 년입니다.

주요 정보

Raj Mehra

최고 경영자

US$1.7m

총 보상

CEO 급여 비율	34.0%
CEO 임기	5.5yrs
CEO 소유권	0.9%
경영진 평균 재임 기간	4.2yrs
이사회 평균 재임 기간	5.5yrs

최근 관리 업데이트

Recent updates

Seelos' expects to commence SLS-005 study in rare neurological disease in H1 2021, shares up 6%

Jan 06

Seelos Therapeutics' trehalose nabs Israel patent

Dec 21

Seelos Therapeutics (SEEL) files for $200M mixed shelf, shares down 8%

Dec 16

CEO 보상 분석

Raj Mehra 의 보수는 Seelos Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-US$27m
Dec 31 2023	US$2m	US$587k	-US$38m
Sep 30 2023	n/a	n/a	-US$51m
Jun 30 2023	n/a	n/a	-US$81m
Mar 31 2023	n/a	n/a	-US$73m
Dec 31 2022	US$2m	US$562k	-US$74m
Sep 30 2022	n/a	n/a	-US$82m
Jun 30 2022	n/a	n/a	-US$73m
Mar 31 2022	n/a	n/a	-US$61m
Dec 31 2021	US$16m	US$523k	-US$66m
Sep 30 2021	n/a	n/a	-US$45m
Jun 30 2021	n/a	n/a	-US$39m
Mar 31 2021	n/a	n/a	-US$33m
Dec 31 2020	US$4m	US$475k	-US$19m
Sep 30 2020	n/a	n/a	-US$23m
Jun 30 2020	n/a	n/a	-US$22m
Mar 31 2020	n/a	n/a	-US$21m
Dec 31 2019	US$709k	US$438k	-US$51m

보상 대 시장: Raj 의 총 보상 ($USD 1.73M )은 US 시장( $USD 683.56K ).

보상과 수익: Raj 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Raj Mehra (64 yo)

5.5yrs

테뉴어

US$1,726,476

보상

Dr. Raj Mehra, Ph D., J.D., was an Independent Director at Larkspur Health Acquisition Corp. since July 2021 and serves as its Director. He was Chairman of Seelos Therapeutics, Inc & serves as Chief Execut...

리더십 팀

이름	위치	테뉴어	보상	소유권
Raj Mehra	CEO, Founder	5.5yrs	US$1.73m	0.89% $ 15.2k
Michael Golembiewski	Chief Financial Officer	2.8yrs	US$846.67k	0.42% $ 7.1k
Anthony Marciano	Chief Communications Officer	5.5yrs	데이터 없음	데이터 없음
Gopal Krishna	Head of Manufacturing & Technical Operations	no data	데이터 없음	데이터 없음
Tim Whitaker	Chief Medical Officer	no data	데이터 없음	데이터 없음
Karen Fusaro	Senior VP & Head of Clinical Operations	1.7yrs	데이터 없음	데이터 없음

4.2yrs

평균 재임 기간

경험이 풍부한 관리: SEEL 의 관리팀은 경험 ( 4.1 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Margaret Dalesandro	Independent Director	2.8yrs	US$89.72k	0.0056% $ 95.6
Richard Pascoe	Independent Chairman	11.3yrs	US$87.72k	0.00084% $ 14.3
Brian Lian	Independent Director	5.5yrs	US$105.22k	0% $ 0

5.5yrs

평균 재임 기간

60yo

평균 연령

경험이 풍부한 이사회: SEEL 의 이사회는 경험(평균 재직 기간 5.4 년)으로 간주됩니다.

Seelos Therapeutics 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Seelos Therapeutics, Inc. Announces Appointment of Richard Pascoe as Chairman of the Board of Directors

Chief Financial Officer recently bought US$100k worth of stock

Seelos Therapeutics, Inc., Annual General Meeting, May 20, 2022

Founder recently bought US$57k worth of stock

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $1.136948 million.

Seelos Therapeutics Announces 1-for-8 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement of $1.00 Per Share of Common Stock for Continued Listing on the Nasdaq Capital Market

Nasdaq to Delist Common Stock of Seelos Therapeutics

Nasdaq to Delist Common Stock of Seelos Therapeutics

Seelos Therapeutics, Inc. Announces Appointment of Richard Pascoe as Chairman of the Board of Directors

New major risk - Market cap size

Seelos Therapeutics, Inc. Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis Study with SLS-005 (IV Trehalose)

New major risk - Revenue and earnings growth

New major risk - Market cap size

Seelos Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $4.000001 million.

Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $4.000001 million.

Consensus EPS estimates upgraded to US$0.41 loss

Seelos Therapeutics, Inc. Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002

Chief Financial Officer recently bought US$100k worth of stock

New major risk - Market cap size

Seelos Therapeutics, Inc. has completed a Follow-on Equity Offering.

Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering.

New major risk - Shareholder dilution

New major risk - Revenue and earnings growth

Consensus EPS estimates upgraded to US$0.34 loss

Seelos Therapeutics Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Under Nasdaq Listing Rule 5550(a)(2)

Seelos Therapeutics Receives Non-Compliance Notice From Nasdaq

New major risk - Revenue and earnings growth

Consensus revenue estimates decrease by 26%

Seelos Therapeutics, Inc. Announces Top Line Results from SLS-002 Phase II Study in Adults with Major Depressive Disorder at Imminent Risk of Suicide

Consensus revenue estimates increase by 80%, EPS downgraded

Seelos Therapeutics, Inc. Announces the Close of Enrollment of Its Registration Directed Study of Sls-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior (Asib) in Adults with Major Depressive Disorder (MDD)

Listing Qualifications Staff of Nasdaq Provides Notice to Seelos Therapeutics for Not Regain Compliance with Rule 5550(a)(2) and Not Eligible for Second 180 Calendar Day Compliance Period

Price target decreased by 12% to US$5.50

No longer forecast to breakeven

Seelos Therapeutics Announces Completion of Enrollment of its Phase II/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis on the HEALEY ALS Platform

Seelos Therapeutics Doses First Patients in an Ethnobridging Study with Sls-002 (Intranasal Racemic Ketamine)

Seelos Therapeutics, Inc. Announces Data Demonstrating Downregulation of Alpha Synuclein in an In Vivo Gene Therapy Study of SLS-004 Utilizing CRISPR-dCas9 in Parkinson's Disease

Seelos Therapeutics Receives Written Notice of Non-Compliance from Nasdaq

Price target decreased to US$5.80

Seelos Therapeutics Doses First Patient in A Registrational Phase II/III Study of SLS-005 in Spinocerebellar Ataxia

Seelos: Data This Year Is Critical

Seelos Therapeutics Inc. Receives A Research and Development Grant from the Michael J. Fox Foundation for Parkinson's Research for SLS-004

Seelos wins Parkinson’s research grant for gene therapy program

Seelos Therapeutics, Inc. Announces Data Demonstrating Statistically Significant Downregulation of mRNA and Reduction of Alpha Synuclein in Vitro Gene Therapy Study

Seelos Therapeutics, Inc. Receives Notice of Allowance in U.S. for an Additional Patent for SLS-007

Price target decreased to US$4.25

Seelos Therapeutics Receives Written Notice from The Nasdaq Stock Market LLC Regarding Minimum Bid Price Requirement

Seelos Therapeutics, Inc., Annual General Meeting, May 20, 2022

Founder recently bought US$57k worth of stock

Price target decreased to US$6.83

Seelos Therapeutics, Inc. Announces Dosing of the First Participants in a Registrational Phase II/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis on the HEALEY ALS Platform

Seelos: FDA Action Makes It Highly Attractive

Seelos Therapeutics, Inc. announced that it has received $20 million in funding from The Lind Partners, LLC

High number of new and inexperienced directors

High number of new and inexperienced directors

Seelos Therapeutics: Shares Have Finally Found A Floor But Risk Remains

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Director Judith Dunn has left the company

Price target decreased to US$8.58

We're Hopeful That Seelos Therapeutics (NASDAQ:SEEL) Will Use Its Cash Wisely

Seelos: Superior Data, But Early Stage

Seelos Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $60.000004 million.

Seelos Therapeutics, Inc. Announces Positive Data from the Open-Label Study of SLS-002

New 90-day high: US$4.75

Seelos Therapeutics Announces Completion of Open-Label Patient Enrollment of Proof of Concept Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior in Patients with Major Depressive Disorder

Seelos Therapeutics Announces Amendment of SLS-002 Agreement to Repurchase a Significant Portion of Royalties for SLS-002 (Intranasal Racemic Ketamine Program)

New 90-day high: US$3.57

Seelos announces issuance of a patent for trehalose (SLS-005) in Australia

New 90-day high: US$2.17

Seelos Therapeutics, Inc. Announces Dosing of the First Patients in its Registrational Proof of Concept Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior

Seelos Therapeutics Regains Compliance with Minimum Bid Price Requirement